2. Metabolic Enzyme/Protease Neuronal Signaling GPCR/G Protein
  3. Adenosine Kinase Adenosine Receptor
  4. ABT-702 hydrochloride

ABT-702 hydrochloride is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 hydrochloride shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 hydrochloride attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 hydrochloride shows analgesic and anti-inflammatory effects in vivo. ABT-702 hydrochloride can be used for diabetic retinopathy research.

For research use only. We do not sell to patients.

CAS No. : 2624336-92-9

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of ABT-702 hydrochloride:

ABT-702 hydrochloride Related Antibodies

Top Publications Citing Use of Products

    ABT-702 hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2023 Jul 26;9(1):262.  [Abstract]

    MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM ABT-702 dihydrochloride, 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed.

    View All Adenosine Receptor Isoform Specific Products:

    View All Isoforms
    Adenosine A1 receptor (A1R) Adenosine A2A receptor (A2AR) Adenosine A2B receptor (A2BR) Adenosine A3 receptor (A3R)

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    ABT-702 hydrochloride is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 hydrochloride shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 hydrochloride attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 hydrochloride shows analgesic and anti-inflammatory effects in vivo. ABT-702 hydrochloride can be used for diabetic retinopathy research[1][2][3].

    In Vitro

    ABT-702 (5-50 μM, 30 min) hydrochloride inhibits amadori-glycated-albumin (AGA)-induced TNF-α release in a dose-dependent manner in AGA-treated microglial cells via the adenosine A2AA receptor (A2AAR)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    ABT-702 hydrochloride Related Antibodies
    In Vivo

    ABT-702 (0.6-100 µmol/kg, i.p. or p.o., single dose) hydrochloride shows dose-dependent analgesic and anti-inflammatory effects in rats[1].
    ABT-702 (1.5 mg/kg, i.p., twice a week for 8 weeks) hydrochloride meliorates diabetic retinopathy in mice by attenuating retinal inflammation, oxidative stress, and cell death[2].
    ABT-702 (3 mg/kg, i.p., 10 minutes pre-FDG) hydrochloride induces significant regional hypometabolism in the cerebellum, mesencephalic region, and medulla in rats[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male rats[1]
    Dosage: 0.6-100 µmol/kg
    Administration: i.p., single dose
    Result: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia.
    Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema.
    Exhibited a non-opioid mechanism of action, as its effects were not reversed by the opioid antagonist naloxone.
    Showed less potential for developing antinociceptive tolerance compared to morphine.
    Animal Model: Male rats[1]
    Dosage: 5-100 µmol/kg
    Administration: p.o., single dose
    Result: Showed potent, dose-dependent antinociceptive effects across multiple pain models, including inflammatory thermal hyperalgesia, formalin test, and nerve injury-induced tactile allodynia.
    Demonstrated significant anti-inflammatory effects by reducing carrageenan-induced paw edema.
    The antinociceptive and anti-inflammatory effects were blocked by selective adenosine receptor antagonists, confirming an adenosine-dependent mechanism.
    Exhibited a non-opioid mechanism of action.
    Showed less potential for developing antinociceptive tolerance compared to morphine.
    Had no significant effects on exploratory locomotor activity at lower analgesic doses.
    Reduced locomotor activity but did not impair motor coordination at higher doses.
    Had no significant effects on heart rate or mean arterial pressure at doses providing maximal anti-hyperalgesia.
    Animal Model: Male C57BL/6J (8 weeks) intraperitoneally injected with Streptozotocin (45 mg/kg, 5 consecutive days) to induce diabetes[2]
    Dosage: 1.5 mg/kg
    Administration: i.p., twice a week for 8 weeks
    Result: Showed no effects on final body weight and blood glucose levels in diabetic mice.
    Showed lower signs of inflammation (ICAM-1, TNF-α, and microglial activation marker Iba1) compared to control animals receiving the vehicle.
    Suppressed the upregulation of A₂A receptor and reduced ENT1 expression.
    Reduced oxidative and nitrosative stress in the retina.
    Blocked the diabetic effect on AK in diabetic mice as compared with vehicle-treated diabetic mice.
    Blocked cell death (decreased cleaved caspase-3 and TUNEL-positive cells) in diabetic mice but did not affect treated normal controls.
    Animal Model: Rats[3]
    Dosage: 3 mg/kg
    Administration: i.p., 10 minutes pre-FDG
    Result: Showed significant regional hypometabolism in the cerebellum, mesencephalic region, and medulla compared to the vehicle-treated rats.
    Molecular Weight

    499.79

    Formula

    C22H20BrClN6O
    CAS No.
    Appearance

    Solid

    Color

    Yellow to orange

    SMILES

    NC1=C(C(C2=CC=CC(Br)=C2)=CC(C3=CC=C(N4CCOCC4)N=C3)=N5)C5=NC=N1.Cl
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    -20°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (100.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0008 mL 10.0042 mL 20.0084 mL
    5 mM 0.4002 mL 2.0008 mL 4.0017 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.0008 mL 10.0042 mL 20.0084 mL 50.0210 mL
    5 mM 0.4002 mL 2.0008 mL 4.0017 mL 10.0042 mL
    10 mM 0.2001 mL 1.0004 mL 2.0008 mL 5.0021 mL
    15 mM 0.1334 mL 0.6669 mL 1.3339 mL 3.3347 mL
    20 mM 0.1000 mL 0.5002 mL 1.0004 mL 2.5011 mL
    25 mM 0.0800 mL 0.4002 mL 0.8003 mL 2.0008 mL
    30 mM 0.0667 mL 0.3335 mL 0.6669 mL 1.6674 mL
    40 mM 0.0500 mL 0.2501 mL 0.5002 mL 1.2505 mL
    50 mM 0.0400 mL 0.2001 mL 0.4002 mL 1.0004 mL
    60 mM 0.0333 mL 0.1667 mL 0.3335 mL 0.8337 mL
    80 mM 0.0250 mL 0.1251 mL 0.2501 mL 0.6253 mL
    100 mM 0.0200 mL 0.1000 mL 0.2001 mL 0.5002 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    ABT-702 hydrochloride Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    ABT-7022624336-92-9ABT702ABT 702Adenosine KinaseAdenosine ReceptorADKP1 receptorinflammationadenosine kinaseadenosine kinasediabetic retinopathyanalgesicA2AARInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ABT-702 hydrochloride
    Cat. No.:
    HY-112482A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.